DD216384A5 - Verfahren zur herstellung von lyophilisierten adsorbierten kombinierten vakzinen - Google Patents

Verfahren zur herstellung von lyophilisierten adsorbierten kombinierten vakzinen Download PDF

Info

Publication number
DD216384A5
DD216384A5 DD84260197A DD26019784A DD216384A5 DD 216384 A5 DD216384 A5 DD 216384A5 DD 84260197 A DD84260197 A DD 84260197A DD 26019784 A DD26019784 A DD 26019784A DD 216384 A5 DD216384 A5 DD 216384A5
Authority
DD
German Democratic Republic
Prior art keywords
antigens
lyophilized
vaccines
concentrated
pertussis
Prior art date
Application number
DD84260197A
Other languages
German (de)
English (en)
Inventor
Zoltan Csizer
Karoly Sikos
Laszlo Bacskai
Istvan Joo
Eleonora Niedermayer
Lajos Rethy
Jozsef Zsidai
Original Assignee
Human Oltoanyagtermelo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Oltoanyagtermelo filed Critical Human Oltoanyagtermelo
Publication of DD216384A5 publication Critical patent/DD216384A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DD84260197A 1983-02-22 1984-02-20 Verfahren zur herstellung von lyophilisierten adsorbierten kombinierten vakzinen DD216384A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU83609A HU188847B (en) 1983-02-22 1983-02-22 Process for producing liophylized combined vaccines

Publications (1)

Publication Number Publication Date
DD216384A5 true DD216384A5 (de) 1984-12-12

Family

ID=10950430

Family Applications (1)

Application Number Title Priority Date Filing Date
DD84260197A DD216384A5 (de) 1983-02-22 1984-02-20 Verfahren zur herstellung von lyophilisierten adsorbierten kombinierten vakzinen

Country Status (18)

Country Link
US (1) US4578270A (it)
JP (1) JPS59196821A (it)
BE (1) BE898955A (it)
CA (1) CA1234048A (it)
CH (1) CH663901A5 (it)
CS (1) CS272759B2 (it)
DD (1) DD216384A5 (it)
DE (1) DE3406419A1 (it)
DK (1) DK82784A (it)
ES (1) ES8506451A1 (it)
FR (1) FR2541116B1 (it)
GB (1) GB2135190B (it)
HU (1) HU188847B (it)
IT (1) IT1196032B (it)
NL (1) NL8400511A (it)
PL (1) PL246306A1 (it)
PT (1) PT78132B (it)
YU (1) YU33284A (it)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
US5139776A (en) * 1987-04-24 1992-08-18 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5290563A (en) * 1989-07-27 1994-03-01 Laboratoire Des Stallergenes Method for combining a mixture of heterogeneous substances with liposomes
MX170503B (es) * 1990-05-10 1993-08-26 Univ Mexico , "procedimiento para obtener un reactivo antigenico util para determinar indirectamente salmonella typhi.
GB9125695D0 (en) * 1991-12-03 1992-01-29 Mastavac Limited Medical preparations
KR100291357B1 (ko) * 1993-01-08 2001-09-17 터베이 피터. 백신제제
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
GB2342922B (en) * 1998-10-19 2002-12-24 Jeyes Group Plc Lavatory cleansing block
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
CA2382652A1 (en) * 1999-08-24 2001-03-01 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
IL153241A0 (en) * 2000-06-08 2003-07-06 Powderject Vaccines Inc Powder compositions
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
CA2548179A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
CN102203002A (zh) * 2007-09-21 2011-09-28 细胞免疫科学公司 纳米治疗性胶态金属组合物和方法
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0916570D0 (en) * 2009-09-21 2009-10-28 Royal Holloway & Bedford New C Method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2085391A (en) * 1934-01-31 1937-06-29 Sharp & Dohme Inc Lyophilic biologically active substances and process of producing the same
US3097140A (en) * 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
GB895073A (en) * 1959-11-23 1962-05-02 Wellcome Found Immunising preparations containing clostridium perfringens toxins and toxoids
US3395219A (en) * 1964-12-11 1968-07-30 Merck & Co Inc Process for production of pertussis antigen
NL6600706A (it) * 1965-02-05 1966-08-08
GB1081796A (en) * 1965-08-13 1967-08-31 Wright Fleming Inst Of Microbi Improvements in or relating to oily adjuvants for water-in-oil emulsions of antigenic materials
US3405218A (en) * 1965-09-22 1968-10-08 Parke Davis & Co Extracting bordetella pertussis antigens with lithium bromide
GB1145320A (en) * 1966-05-20 1969-03-12 Ustav Ser A Ockovacich Latek O Process for the preparation of bacterial cultures for vaccines against pertussis and
GB1152607A (en) * 1967-03-08 1969-05-21 Pfizer Ltd Antigenic Compositions
GB1218277A (en) * 1968-08-20 1971-01-06 Miles Lab Dry water-dispersible aluminium hydroxide gels
US3599150A (en) * 1969-08-01 1971-08-10 Miles Lab Stabilized aluminum hydroxide suspensions
FR2181426B1 (it) * 1972-04-06 1974-12-20 Pasteur Institut
FR2227861B1 (it) * 1973-05-04 1976-07-02 Anvar
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
DE2461439C3 (de) * 1974-12-24 1980-03-20 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines

Also Published As

Publication number Publication date
CS272759B2 (en) 1991-02-12
HU188847B (en) 1986-05-28
GB2135190A (en) 1984-08-30
IT1196032B (it) 1988-11-10
BE898955A (fr) 1984-08-20
CA1234048A (en) 1988-03-15
FR2541116B1 (fr) 1988-07-15
US4578270A (en) 1986-03-25
NL8400511A (nl) 1984-09-17
CH663901A5 (de) 1988-01-29
ES529961A0 (es) 1985-07-16
DK82784D0 (da) 1984-02-21
FR2541116A1 (fr) 1984-08-24
GB2135190B (en) 1986-10-22
ES8506451A1 (es) 1985-07-16
PT78132A (en) 1984-03-01
YU33284A (en) 1987-10-31
DE3406419A1 (de) 1984-08-23
PL246306A1 (en) 1985-02-27
JPS59196821A (ja) 1984-11-08
IT8419729A0 (it) 1984-02-21
PT78132B (en) 1986-05-19
GB8403921D0 (en) 1984-03-21
CS122584A2 (en) 1990-06-13
DK82784A (da) 1984-08-23

Similar Documents

Publication Publication Date Title
DD216384A5 (de) Verfahren zur herstellung von lyophilisierten adsorbierten kombinierten vakzinen
EP1648485B2 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
DE69532810T2 (de) Intravenöse alendronatformulierungen
DE2362121C2 (de) Adjuvans-Zusammensetzungen für Antigen-Präparate
DE2725204C2 (de) Verfahren zum Herstellen eines die unspezifische Immunität stimulierenden löslichen Mikroorganismenextrakts und diesem enthaltendes Arzneimittel
DE69029765T2 (de) Stabilisierung von hochgereinigten Proteinen
EP0619737A1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
EP0012156A1 (de) Immunserumglobulin (ISG)-Präparate und Verfahren zu ihrer Herstellung
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE19511276C2 (de) Adjuvans auf der Basis kolloidaler Eisenverbindungen
DE1942161A1 (de) Trockenes,in Wasser dispergierbares Aluminiumhydroxidgel mit darauf absorbierter Antikoerper produzierender oder immunisierender Substanz
DE2440529B2 (de) Hyaluronidase-Präparat aus menschlicher Plazenta
EP0363835A1 (de) Verwendung von Zink- oder Eisenhydroxid zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen
DE1907098C3 (de) Träger für injizierbare Arzneimittel
EP0120835A2 (de) Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachenden Substanzen
DE602004006024T2 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
EP0255651B1 (de) Mittel zur Therapie faktor VIII-resistenter Hämophilie A und Verfahren zu seiner Herstellung
DE1492243C3 (de) Injizierbare Impfstoffe
DE2448530B2 (de) Verfahren zum Herstellen von Derivaten des Diphtherietoxins und diese enthaltende Mittel
DE69001110T2 (de) Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon.
DE3873825T2 (de) Die proteinabsorption verbessernde stoffe.
DE1942900C3 (de) Verfahren zur Abtrennung von L-Asparaginase aus Bakterienkulturen, danach hergestellte L-Asparaginase und diese enthaltendes therapeutisches Mittel
EP0022426A2 (de) Nasalpräparate und Verfahren zu deren Herstellung
DE3877015T2 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
EP0123142B1 (de) Verfahren zur Stabilisierung von Hämatin

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee